CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 30 target
Drug / intervention
19(T2)28z1xx TRAC T cellbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05757700
NCT05757700Phase 1ActiveOn TrackUpdated 2mo ago
CompareCT.gov

A Phase I Study of T-cell Receptor Alpha Constant (TRAC) Locus Integrated CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With CD19+ Relapsed or Refractory Large B-Cell Lymphoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Mar 7, 2023·Updated Apr 22, 2026

In Brief

A Phase 1 clinical trial evaluating 19(T2)28z1xx TRAC T cell for B-Cell Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 30 participants across 1 site.

Detailed Summary

The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, High-grade B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
CountriesUnited States
CollaboratorsTakeda

Timeline

Phase 1Active
2024202520262027
First PostedMar 7, 2023
Enrollment StartFeb 23, 2023
Primary CompletionFeb 23, 2027
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 3.3 years agoPrimary completion in 8 months

Interventions

19(T2)28z1xx TRAC T cellbiological

Participants will be treated with escalating doses of modified T cells. Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6